Endometrial Undifferentiated Carcinoma
Associated Genetic Biomarkers
NCI Definition: A primary carcinoma of the endometrium characterized by the presence of malignant cells that lack evidence of differentiation. 
Endometrial undifferentiated carcinomas most frequently harbor alterations in TP53, PTEN, CTNNB1, ARID1A, and PIK3CA .
PTEN Mutation, TP53 Mutation, CTNNB1 Mutation, TP53 c.217-c.1178 Missense, and TP53 Missense are the most common alterations in endometrial undifferentiated carcinoma .
There are 10 clinical trials for endometrial undifferentiated carcinoma, of which 8 are open and 2 are completed or closed. Of the trials that contain endometrial undifferentiated carcinoma as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 6 are phase 2 (5 open), and 2 are phase 3 (2 open).
Deficient, ER, and MLH1 are the most frequent gene inclusion criteria for endometrial undifferentiated carcinoma clinical trials .
Pembrolizumab, placebo, and abemaciclib are the most common interventions in endometrial undifferentiated carcinoma clinical trials.
Significant Genes in Endometrial Undifferentiated Carcinoma
POLE is altered in 16.67% of endometrial undifferentiated carcinoma patients .
POLE is an inclusion eligibility criterion in 1 clinical trial for endometrial undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and endometrial undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.